TABLE 3.
Protection of neonatal mice from GBS infection by passive immunization with III-α9r conjugate vaccine
| Antiserum | Challenge strain | No. alive/total no. tested (% survival)a |
|---|---|---|
| III-α9r | A909 | 21/36 (58)* |
| III-α9r | M781 | 36/36 (100)** |
| Nine-repeat alpha C protein | A909 | 18/40 (45)*** |
| III-TT (positive control) | M781 | 43/44 (98)**** |
| Preimmunization (negative control) | A909 | 9/45 (20) |
| Preimmunization (negative control) | M781 | 3/45 (7) |
a
Significant differences in protection levels for different antisera were identified by Fisher’s exact test. Compared to preimmunization serum after challenge with strain A909, P values were as follows: *, 0.0001; ***, 0.0193. Compared to preimmunization serum after challenge with strain M781, P values were as follows: ** and ****, <0.0001.